Incyte Corporation Stock News

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.

Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.

The shares of Incyte Corporation   ( NASDAQ:INCY) are down 5.3% at $68.33 at last check, after the U.S. Food and Drug Administration (FDA) failed to approve the extended-release version of the compan

Incyte stock toppled Friday after the FDA unexpectedly rejected an extended-release version of its blockbuster drug, Jakafi. The post Incyte Stock Dives On Surprise Rejection For Updated Jakafi appear

The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.

Incyte (INCY) gets accelerated approval for retifanlimab-dlwr for the treatment of adults with metastatic or recurrent locally advanced merkel cell carcinoma.

Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation.

Incyte (INCY) announces positive data on povorcitinib and Opzelura for the treatment of nonsegmental vitiligo.

Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendati

Is the Fed done jacking up interest rates or not? Angst over that question is torturing the stock market — but a handful of S&P 500 stocks aren't worried.

Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.

U.S. equities posted gains on Feb. 7 after Fed Chair Jerome Powell said that inflation was easing but noted that rate hikes would continue if needed.

Incyte Corporation (NASDAQ:INCY ) Q4 2022 Earnings Conference Call February 7, 2023 8:00 AM ET Company Participants Christine Chiou - Head, Investor Relations Hervé Hoppenot - Chairman, President and

Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.